DE60218852D1 - Verbindungen - Google Patents

Verbindungen

Info

Publication number
DE60218852D1
DE60218852D1 DE60218852T DE60218852T DE60218852D1 DE 60218852 D1 DE60218852 D1 DE 60218852D1 DE 60218852 T DE60218852 T DE 60218852T DE 60218852 T DE60218852 T DE 60218852T DE 60218852 D1 DE60218852 D1 DE 60218852D1
Authority
DE
Germany
Prior art keywords
links
pharmaceuticals
specifically
relates
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60218852T
Other languages
English (en)
Other versions
DE60218852T2 (de
Inventor
Wai Ngor Chan
Amanda Johns
Christopher Norbert Johnson
Riccardo Novelli
Roderick Alan Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE60218852D1 publication Critical patent/DE60218852D1/de
Application granted granted Critical
Publication of DE60218852T2 publication Critical patent/DE60218852T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
DE60218852T 2001-06-28 2002-06-25 Verbindungen Expired - Lifetime DE60218852T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0115862 2001-06-28
GBGB0115862.5A GB0115862D0 (en) 2001-06-28 2001-06-28 Compounds
GBGB0130347.8A GB0130347D0 (en) 2001-06-28 2001-12-19 Compounds
GB0130347 2001-12-19
PCT/EP2002/007007 WO2003002559A2 (en) 2001-06-28 2002-06-25 Piperidine compounds for use as orexin receptor antagonist

Publications (2)

Publication Number Publication Date
DE60218852D1 true DE60218852D1 (de) 2007-04-26
DE60218852T2 DE60218852T2 (de) 2007-12-13

Family

ID=26246260

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60218852T Expired - Lifetime DE60218852T2 (de) 2001-06-28 2002-06-25 Verbindungen

Country Status (9)

Country Link
US (2) US7423052B2 (de)
EP (1) EP1406897B1 (de)
JP (1) JP4328615B2 (de)
AT (1) ATE356818T1 (de)
AU (1) AU2002352633A1 (de)
DE (1) DE60218852T2 (de)
ES (1) ES2283609T3 (de)
GB (2) GB0115862D0 (de)
WO (1) WO2003002559A2 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089800A2 (en) * 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
AU2002253361B2 (en) * 2001-05-05 2006-08-17 Smithkline Beecham P.L.C. N-aroyl cyclic amines
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
IL159041A0 (en) * 2001-06-28 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0127145D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Compounds
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
US7279578B2 (en) 2002-10-11 2007-10-09 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
ZA200508298B (en) 2003-04-11 2007-01-31 Ptc Therapeutics Inc 1,2,4-oxadiazole benzoic acid compounds
CA2520839A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Quinoxalinone-3- one derivatives as orexin receptor antagonists
TW200533664A (en) 2004-02-18 2005-10-16 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
BRPI0508263B8 (pt) 2004-03-01 2021-05-25 Idorsia Pharmaceuticals Ltd derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
US7501395B2 (en) 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
JP2008545008A (ja) * 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
MX2008012515A (es) 2006-03-30 2008-11-19 Ptc Therapeutics Inc Metodos para la produccion de proteina funcional a partir de adn que tiene una mutacion sin sentido y el tratamiento de trastornos asociados con la misma.
EP2049110B1 (de) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Verbrückte diazepanorexin-rezeptorantagonisten
US8273738B2 (en) 2006-09-05 2012-09-25 Kyowa Hakko Kirin Co., Ltd. Imidazole derivatives
JP2010504957A (ja) * 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体
ATE496043T1 (de) 2006-12-01 2011-02-15 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
AR064561A1 (es) * 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
EP2150114A4 (de) 2007-05-18 2012-01-18 Merck Sharp & Dohme Oxo-verbrückte diazepanorexin-rezeptorantagonisten
EP2150115B1 (de) 2007-05-23 2013-09-18 Merck Sharp & Dohme Corp. Cyclopropylpyrrolidinorexin-rezeptorantagonisten
RU2470021C2 (ru) 2007-05-23 2012-12-20 Мерк Шарп Энд Домэ Корп. Пиридилпиперидиновые антагонисты рецептора орексинов
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
GB0712888D0 (en) * 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
EP2183246A2 (de) 2007-07-27 2010-05-12 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo-[3,3,0]-octanderivate
US8288411B2 (en) * 2007-09-24 2012-10-16 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
CL2008003085A1 (es) 2007-10-19 2009-10-09 Astrazeneca Ab Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales.
ATE528295T1 (de) 2007-12-28 2011-10-15 Actelion Pharmaceuticals Ltd Trisubstituierte 3,4-dihydro-1h-isochinolin- verbindung, verfahren zu ihrer herstellung und ihre anwendung
CN101918361B (zh) * 2008-02-12 2014-05-28 弗·哈夫曼-拉罗切有限公司 哌啶磺酰胺衍生物
ATE555107T1 (de) 2008-02-21 2012-05-15 Actelion Pharmaceuticals Ltd 2-aza-bicyclo-ä2,2,1-üheptan-derivate
GB0806536D0 (en) * 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
EP2318367B1 (de) * 2008-04-30 2013-03-20 Actelion Pharmaceuticals Ltd. Piperidin- und pyrrolidinverbindungen
EP2350066B1 (de) 2008-10-21 2013-08-28 Merck Sharp & Dohme Corp. 2,5-disubstiuierte piperidine als antagonisten des orexinrezeptors
US8710076B2 (en) * 2008-10-21 2014-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
CA2740190A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
CA2745420A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
US8609696B2 (en) 2008-12-18 2013-12-17 Boehringer Ingelheim International Gmbh Serotonin 5-HT2B receptor inhibitors
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
JP2012524760A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド オレキシンアンタゴニストとして使用される３−アザビシクロ［４．１．０］ヘプタン
WO2011023585A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
JP2013502447A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
US9242970B2 (en) * 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
BR112014001083B8 (pt) * 2011-09-19 2022-06-14 Suven Life Sciences Ltd Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9150566B2 (en) * 2011-11-08 2015-10-06 Actelion Pharmaceuticals Ltd. 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists
CA2863413A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
EA029899B1 (ru) 2012-06-04 2018-05-31 Идорсиа Фармасьютиклз Лтд Производные бензимидазол-пролина
BR112014031109A2 (pt) 2012-06-15 2017-06-27 Taisho Pharmaceutical Co Ltd derivado de anel heteroaromático de alquila de cadeia ramificada
HUE031538T2 (en) * 2012-06-15 2017-07-28 Taisho Pharmaceutical Co Ltd 1,3-oxazolidine or 1,3-oxazinane compounds as orexin receptor antagonists
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
WO2015018027A1 (en) * 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Thiazole orexin receptor antagonists
WO2015018029A1 (en) * 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Oxazole orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
TWI664177B (zh) 2013-12-03 2019-07-01 瑞士商愛杜西亞製藥有限公司 晶形
DK3077391T3 (en) 2013-12-04 2018-10-22 Idorsia Pharmaceuticals Ltd USE OF BENZIMIDAZOLE PROLINE DERIVATIVES
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
WO2015087853A1 (ja) * 2013-12-13 2015-06-18 大正製薬株式会社 オキサジナン化合物の結晶形及びその製造方法
TWI695717B (zh) 2014-03-06 2020-06-11 美商 Ptc 治療公司 １,２,４-二唑苯甲酸之鹽及醫藥組合物
AR101558A1 (es) 2014-08-13 2016-12-28 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores del receptor de orexina
WO2016086357A1 (en) * 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Methyl oxazole orexin receptor antagonists
WO2016086358A1 (en) * 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Hydroxymethyl piperidine orexin receptor antagonists
WO2016095204A1 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor antagonists
JP2018188364A (ja) * 2015-10-02 2018-11-29 大正製薬株式会社 複素芳香環誘導体
JP2018531975A (ja) 2015-10-30 2018-11-01 ピーティーシー セラピューティクス，インコーポレーテッド てんかんの治療方法
TWI710557B (zh) 2016-02-12 2020-11-21 美商伊歐拉斯治療學公司 作為食慾素受體調節劑之經鹵素取代之六氫吡啶
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
US20220259224A1 (en) * 2019-06-04 2022-08-18 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
CN110437092B (zh) * 2019-07-11 2022-06-10 泓博智源(开原)药业有限公司 一种替格瑞洛关键中间体芳族环丙烷酰胺的制备方法
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
WO2024019978A2 (en) * 2022-07-19 2024-01-25 Rutgers, The State University Of New Jersey Therapeutic combinations and methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3810097B2 (ja) * 1993-01-15 2006-08-16 明治製菓株式会社 ピロリジン−２−イルカルボニル複素環式化合物誘導体
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
US6372757B1 (en) * 1998-05-08 2002-04-16 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
DE69920923T2 (de) 1998-07-24 2005-10-20 Teijin Ltd. Anthranilsäurederivate
PT1102763E (pt) 1998-08-07 2005-01-31 Applied Research Systems Mimeticos fsh para o tratamento da infertilidade
WO2000012077A1 (en) 1998-09-01 2000-03-09 Bristol-Myers Squibb Company Potassium channel inhibitors and method
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
CA2354774C (en) 1998-12-18 2009-05-26 Schering Corporation Farnesyl protein transferase inhibitors
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
US6596730B1 (en) 1999-02-12 2003-07-22 Smithkline Beecham P.L.C. Phenyl urea and phenyl thiourea derivatives
KR20020006626A (ko) 1999-02-26 2002-01-23 폴락 돈나 엘. 신규한 술폰아미드 화합물 및 그의 용도
WO2000071510A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
AU2525701A (en) 1999-12-14 2001-06-25 Sanofi-Synthelabo Derivatives of quinazolinedione phthalimide, preparations thereof and their therapeutic uses
AU763356C (en) 1999-12-27 2004-08-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
ATE293101T1 (de) 2000-06-16 2005-04-15 Smithkline Beecham Plc Piperidine zur verwendung als orexin rezeptor antagonisten
DE60108420T2 (de) 2000-11-28 2005-12-22 Smithkline Beecham P.L.C., Brentford Morpholinderivate als antagonisten an orexinrezeptoren
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
AU2002253361B2 (en) 2001-05-05 2006-08-17 Smithkline Beecham P.L.C. N-aroyl cyclic amines
IL159041A0 (en) 2001-06-28 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
AU2003262516A1 (en) 2002-09-18 2004-04-08 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists

Also Published As

Publication number Publication date
AU2002352633A1 (en) 2003-03-03
JP4328615B2 (ja) 2009-09-09
US20040215014A1 (en) 2004-10-28
US20090082390A1 (en) 2009-03-26
GB0115862D0 (en) 2001-08-22
ES2283609T3 (es) 2007-11-01
EP1406897A2 (de) 2004-04-14
ATE356818T1 (de) 2007-04-15
JP2005501026A (ja) 2005-01-13
US7943645B2 (en) 2011-05-17
US7423052B2 (en) 2008-09-09
WO2003002559A3 (en) 2003-08-28
EP1406897B1 (de) 2007-03-14
GB0130347D0 (en) 2002-02-06
WO2003002559A2 (en) 2003-01-09
DE60218852T2 (de) 2007-12-13

Similar Documents

Publication Publication Date Title
ATE356818T1 (de) Verbindungen
ATE344261T1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
NO20035739L (no) N-aroyl syklisk aminderivater som orexin reseptorantagonister
ATE405561T1 (de) Ethylenediaminderivate und ihre verwendung als orexinrezeptorantagonisten
WO2004069793A3 (en) Novel 2-substituted cyclic amines as calcium sensing receptor modulators
AU2002341123A1 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
NO20091976L (no) Nye forbindelser
SMAP200600024A (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosia
BR0115436A (pt) Compostos de piperazinilpirazina atuando como antagonistas do receptor 5ht-2 de serotonina
NO20021450D0 (no) Cykliske aminforbindelser som CCR5 antagonister
DE60224521D1 (de) N-aroyl zyklische amine
ATE422198T1 (de) Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten
ATE372768T1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste
ATE478049T1 (de) Phosphodiesterase-4-inhibitoren, einschliesslich n-substituierter diarylaminanaloga
ATE360629T1 (de) Photoaktivierbare stickstoffbasen
BR0115400A (pt) Compostos de piperazinilpirazina atuando como agonistas ou antagonistas do receptor 5ht-2 de serotonina
EA200701122A1 (ru) Потенциаторы рецепторов глутамата
CY1107368T1 (el) Νεα παραγωγα 4-βενζυλιδενο-πιπεριδινης
BRPI0414599A (pt) pirrol-indóis substituìdos
CY1107254T1 (el) Μη πεπτιδικοι ανταγωνιστες της ωραδυκινινης και φαρμακευτικες συνθεσεις αυτων
DE60238709D1 (de) 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren
NO20040877L (no) Cyklisk aminforbindelse.
DE60322237D1 (de) 6h-thienä2,3-büpyrrolderivate als antagonisten des gonadotropin-freisetzenden hormons (gnrh)
BRPI0510407A (pt) derivados de 3-amino-2-fenilpirrolidina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition